SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors rally around the company's optical interconnect technology, with strong bullish sentiment following a CFO interview that dismissed short-seller concerns and highlighted ongoing engagement with hyperscalers. The community is actively discussing the stock's massive trading volume and the potential for a significant re-rating as the company moves toward scaling production and securing major purchase orders.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing significant upward momentum driven by intense retail interest and investor optimism regarding its gallium nitride (GaN) power chip technology, which is viewed as a critical component for future AI data center infrastructure. While bulls are encouraged by potential long-term partnerships and the company's role in next-gen power architectures, the community is actively debating whether this price action is a fundamental re-rating or a speculative short squeeze, with many participants warning of the company's current lack of profitability.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing significant attention as investors await clinical updates and a potential partnership or buyout, following recent institutional stake increases and the presentation of preclinical data for SLS009. The community is deeply divided, with bulls pointing to institutional accumulation and the potential curative nature of their pipeline, while bears voice skepticism regarding the company's financial history and the timeline for trial data releases.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense community engagement as investors speculate on a major trend reversal, fueled by positive housing market data and optimism regarding the company's integrated transaction model. Traders are actively discussing the stock's short-squeeze potential, citing significant short interest and technical breakouts that have many comparing its growth trajectory to other high-beta market plays.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in popularity as the community rallies around its 2011 origin as the first-ever cryptocurrency meme, positioning it as an authentic, culture-driven counterpart to Bitcoin. Investors are actively highlighting its deep historical lore and recent influx of high-conviction holdings as catalysts for its potential to reach significant market milestones.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

The community is actively discussing ProShares Ultra Bloomberg Crude Oil (UCO) amidst extreme volatility in energy markets, fueled by fears of a supply crunch and a potential blockade in the Strait of Hormuz. Investors are intensely debating the impacts of geopolitical tensions on oil prices, with many questioning the efficacy of the ETF's leverage, while others argue that structural supply shortages could drive further upside.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra Corp is trending as investors react to a significant 20-year power purchase agreement with Meta Platforms to supply nuclear energy to support data center growth, fueling bullish momentum. Despite recent market volatility and retail investor skepticism regarding valuation, the community is actively debating the stock's role as a cornerstone of AI infrastructure and debating entry points amidst broader energy sector rotations.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is surging following the release of positive registrational Phase 2 data for miv-cel, with the community highlighting its potential to become the first approved CAR T-cell therapy for autoimmune diseases like stiff-person syndrome. Investors are actively discussing the strong clinical endpoints and future commercialization prospects, while closely watching for potential acquisition interest given the company's strong institutional backing and best-in-class trial results.

Based Chad

CHAD is capturing significant community attention on the Base network, driven by its branding as the most globally recognizable internet meme and recent high-profile engagement from figures including Coinbase leadership. Investors are actively discussing the project's supply-shock mechanics, ongoing buyback initiatives, and upcoming developments like AAA gaming, with many proponents viewing it as a long-term accumulation play reminiscent of established legacy memecoins.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending as investors digest new clinical data from the ASH conference regarding its R289 IRAK1/4 inhibitor, which demonstrated red blood cell transfusion independence in heavily pre-treated MDS patients. The community is actively discussing the stock's strong commercial momentum and recent earnings performance, while speculating on the potential for strategic acquisitions or partnerships given the company's profitable status and pipeline progression.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AVIR is a textbook breakout! 🧬📈  
 
Reclaiming $4.14 as support is the massive pivot bulls have been waiting for. With a fresh Golden Cross and Phase 3 HCV data looming in mid-2026, the $301M cash cushion makes this a high-conviction &quot;safety&quot; play in biotech. 🛡️🚀 
 
🐂 Bulls: Must hold $4.14 and clear $4.34 (52-week high) to target $6.12.  
🐻 Bears: Looking for a break below $3.80 to invalidate the breakout. 
 
Confirming level: $4.34 
 
#AVIR #Biotech #AteaPharma #GoldenCross #hovdid